Johnson & Johnson's Top Investment Among Its Biotech Holdings
Johnson & Johnson (JNJ) has disclosed its investments in a portfolio of biotechnology and medical technology stocks through its latest 13F filing. The report, as of June 30, 2026, shows J&J holds stakes in 15 companies across various market caps, with the majority being small-cap or micro/nano-cap firms. Among these holdings, Protagonist Therapeutics (PTGX) stands out due to its significant value and strategic importance. Protagonist has an approved drug, Icotyde, for treating moderate-to-severe plaque psoriasis, developed jointly with J&J. The company is also in late-stage trials for other indications such as Crohn's disease and ulcerative colitis. Additionally, Protagonist’s candidate rusfertide could receive FDA approval by August 2026 for the treatment of polycythemia vera, a rare blood cancer. Protagonist has delivered strong financial performance this year with a $162.8 million profit in Q2 and ended the quarter with over $849 million in cash. Its shares have surged by 65% year-to-date as of August 28, making it one of J&J’s most valuable investments.
Tickers: $CBRS $CTNM $FATE $JNJ $LAB $LEGN $MGTX $NBTX $NMRA $PRCT $PTGX $TAK $VOR $XNCR